1. Metabolic Enzyme/Protease
  2. HIF/HIF Prolyl-Hydroxylase

Daprodustat (Synonyms: GSK1278863)

Cat. No.: HY-17608 Purity: 99.95%
Data Sheet SDS Handling Instructions

Daprodustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease.

For research use only. We do not sell to patients.
Daprodustat Chemical Structure

Daprodustat Chemical Structure

CAS No. : 960539-70-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
5 mg $100 In-stock
10 mg $150 In-stock
50 mg $450 In-stock
100 mg $750 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Daprodustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease.

In Vitro

GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis[1]. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03029208 GlaxoSmithKline Anaemia May 11, 2017 Phase 3
NCT03029247 GlaxoSmithKline|Quintiles, Q2 Solutions, HemoCue, ERT Anaemia July 21, 2017 Phase 2
NCT02969655 GlaxoSmithKline Anaemia November 21, 2016 Phase 3
NCT03223337 GlaxoSmithKline Anaemia July 31, 2017 Phase 1
NCT02879305 GlaxoSmithKline Anaemia June 14, 2014 Phase 3
NCT02876835 GlaxoSmithKline Anaemia September 27, 2016 Phase 3
NCT01673555 GlaxoSmithKline Anaemia May 15, 2012 Phase 1
NCT02243306 GlaxoSmithKline Anaemia October 24, 2014 Phase 1
NCT01376232 GlaxoSmithKline|Octagon Research Solutions, Incoporated Anaemia November 8, 2010 Phase 1
NCT02231190 GlaxoSmithKline Tendon Injuries January 15, 2015 Phase 1
NCT00750256 GlaxoSmithKline Anaemia July 7, 2008 Phase 1
NCT01920594 GlaxoSmithKline Surgical Procedures October 2013 Phase 2
NCT02075463 GlaxoSmithKline Anemia June 1, 2014 Phase 2
NCT02829320 GlaxoSmithKline Anaemia August 1, 2016 Phase 3
NCT02689206 GlaxoSmithKline Anaemia February 17, 2016 Phase 2
NCT02371603 GlaxoSmithKline Anaemia February 11, 2015 Phase 1
NCT02791763 GlaxoSmithKline Anaemia June 2016 Phase 3
NCT01977573 GlaxoSmithKline Anaemia October 2013 Phase 2
NCT02019719 GlaxoSmithKline Anaemia November 5, 2013 Phase 2
NCT02293148 GlaxoSmithKline Anaemia November 17, 2014 Phase 1
NCT01319006 GlaxoSmithKline Anaemia February 25, 2011 Phase 1
NCT01406340 GlaxoSmithKline Anaemia August 30, 2011 Phase 1
NCT02348372 GlaxoSmithKline Anaemia March 31, 2011 Phase 1
NCT01977482 GlaxoSmithKline Anaemia November 1, 2013 Phase 2
NCT01831804 GlaxoSmithKline Wound Healing June 17, 2013 Phase 1
NCT02135848 GlaxoSmithKline Vascular Disease, Peripheral October 2010 Phase 2
NCT01587898 GlaxoSmithKline|PPD Anaemia May 2012 Phase 2
NCT01587924 GlaxoSmithKline|PPD Anaemia May 2012 Phase 2
View MoreCollapse
References
Molecular Weight

393.43

Formula

C₁₉H₂₇N₃O₆

CAS No.

960539-70-2

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: < 6.8 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.95%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Daprodustat
Cat. No.:
HY-17608
Quantity: